{"id":"rosuvastatin-crestor","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Myalgia (muscle pain)"},{"rate":"5-7","effect":"Headache"},{"rate":"2-4","effect":"Asthenia (weakness)"},{"rate":"1-3","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"}]},"_chembl":{"chemblId":"CHEMBL1744447","moleculeType":"Small molecule","molecularWeight":"1001.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking HMG-CoA reductase, rosuvastatin reduces intracellular cholesterol levels, which triggers upregulation of LDL receptors on hepatocytes. This increases the clearance of LDL cholesterol from the bloodstream, resulting in significant reductions in plasma LDL-C, total cholesterol, and triglycerides. Rosuvastatin is a high-potency statin with superior LDL-lowering efficacy compared to many other statins.","oneSentence":"Rosuvastatin inhibits HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step of cholesterol synthesis in the liver.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:09.550Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and mixed dyslipidemia"},{"name":"Primary prevention of cardiovascular disease in at-risk patients"},{"name":"Secondary prevention of cardiovascular events in patients with established coronary heart disease"}]},"trialDetails":[{"nctId":"NCT07223671","phase":"PHASE1","title":"Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-12-31","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT06899061","phase":"PHASE1","title":"Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-25","conditions":"Advanced Solid Malignancies","enrollment":41},{"nctId":"NCT07431866","phase":"PHASE1","title":"A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-18","conditions":"Healthy","enrollment":39},{"nctId":"NCT05850091","phase":"PHASE4","title":"Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-12-07","conditions":"Coronary Artery Disease","enrollment":200},{"nctId":"NCT07216482","phase":"PHASE3","title":"A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-11","conditions":"Hyperlipidemia","enrollment":975},{"nctId":"NCT07474649","phase":"PHASE3","title":"A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events","status":"NOT_YET_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2026-06-01","conditions":"Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia","enrollment":103},{"nctId":"NCT07300280","phase":"PHASE1","title":"A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-29","conditions":"Healthy","enrollment":60},{"nctId":"NCT07218900","phase":"PHASE2","title":"A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-13","conditions":"Dyslipidaemia","enrollment":76},{"nctId":"NCT07460960","phase":"PHASE2","title":"TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men","status":"RECRUITING","sponsor":"Lomonosov Moscow State University Medical Research and Educational Center","startDate":"2026-03-05","conditions":"Erectile Dysfunction Due to Arterial Disease, Atheroscleroses, Erectile Disfunction","enrollment":150},{"nctId":"NCT02592317","phase":"PHASE1","title":"A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2016-02-12","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":23},{"nctId":"NCT07372625","phase":"PHASE1","title":"A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.","status":"RECRUITING","sponsor":"PMV Pharmaceuticals, Inc","startDate":"2026-02-04","conditions":"TP53 Y220C Mutation, Advanced Solid Tumors","enrollment":14},{"nctId":"NCT07359105","phase":"NA","title":"Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)","status":"RECRUITING","sponsor":"Sin Gon Kim","startDate":"2026-03-09","conditions":"Dyslipidemia Associated With Type II Diabetes Mellitus","enrollment":2186},{"nctId":"NCT07349394","phase":"PHASE1","title":"Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2026-01-12","conditions":"Cystic Fibrosis","enrollment":18},{"nctId":"NCT06834932","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-12-06","conditions":"Dyslipidaemia","enrollment":360},{"nctId":"NCT06975111","phase":"PHASE2, PHASE3","title":"Focusing on the Menopausal Transition to Improve Mid-Life Women's Health","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-03-01","conditions":"Menopause, Menopause Hot Flashes, Menopause Related Conditions","enrollment":200},{"nctId":"NCT06982131","phase":"PHASE1","title":"A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-06-04","conditions":"Overweight, Obesity","enrollment":40},{"nctId":"NCT06686615","phase":"","title":"A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2025-02-12","conditions":"Primary Hypercholesterolemiia, Mixed Dyslipidemia","enrollment":2000},{"nctId":"NCT07088913","phase":"PHASE1","title":"A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-07-28","conditions":"Healthy Participants","enrollment":20},{"nctId":"NCT07446400","phase":"PHASE1","title":"A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together","status":"NOT_YET_RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-03-20","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT04098003","phase":"PHASE4","title":"Investigation of the Gut Microbiome and Statin Response","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sony Tuteja","startDate":"2020-02-06","conditions":"Healthy Volunteers","enrollment":62},{"nctId":"NCT06696820","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Xiang Luo","startDate":"2024-11-29","conditions":"Acute Ischemic Stroke","enrollment":429},{"nctId":"NCT06488105","phase":"PHASE2","title":"Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-08-05","conditions":"Lipid Disorder, Hypercholesterolemia, Cardiovascular Diseases","enrollment":130},{"nctId":"NCT06979973","phase":"PHASE1","title":"A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2025-05-14","conditions":"Healthy","enrollment":24},{"nctId":"NCT07232069","phase":"PHASE3","title":"PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-07-01","conditions":"Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression, Prevention & Control","enrollment":1500},{"nctId":"NCT05912387","phase":"EARLY_PHASE1","title":"Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-05-31","conditions":"Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases","enrollment":15},{"nctId":"NCT06538649","phase":"EARLY_PHASE1","title":"Effect of Statins on Crohn's Disease","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-12-12","conditions":"Crohn's Ileocolitis, Crohn Disease","enrollment":20},{"nctId":"NCT03016819","phase":"PHASE3","title":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","status":"RECRUITING","sponsor":"Advenchen Laboratories, LLC","startDate":"2017-08-15","conditions":"Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma","enrollment":325},{"nctId":"NCT07432516","phase":"NA","title":"Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-02","conditions":"Coronary Artery Disease","enrollment":4400},{"nctId":"NCT03417388","phase":"PHASE4","title":"Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-02-09","conditions":"Coronary Artery Disease","enrollment":2476},{"nctId":"NCT07235748","phase":"PHASE1","title":"Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier (I.R.I.S.)","startDate":"2025-10-07","conditions":"Healthy Adult Participants","enrollment":28},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT07222098","phase":"PHASE1","title":"A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-19","conditions":"Healthy","enrollment":16},{"nctId":"NCT07401017","phase":"NA","title":"The Effects of Rosuvastatin on Running Training Adaptation and Safety","status":"NOT_YET_RECRUITING","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2026-03-01","conditions":"Dyslipidemia, Long-Distance Running, Endurance Training","enrollment":40},{"nctId":"NCT07389304","phase":"PHASE1","title":"[Effects of Selected Statins on Cardiovascular Parameters in Healthy Volunteers]","status":"NOT_YET_RECRUITING","sponsor":"Shaheed Benazir Bhutto University Sheringal Dir Upper","startDate":"2026-03-01","conditions":"Lipid Profile,Blood Pressure","enrollment":100},{"nctId":"NCT07378293","phase":"PHASE1","title":"Effects of Selected Statins on Blood Glucose Levels in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Shaheed Benazir Bhutto University Sheringal Dir Upper","startDate":"2026-03-01","conditions":"Diabete Mellitus, Lipid Profile","enrollment":100},{"nctId":"NCT06981299","phase":"PHASE1","title":"A Phase 1 Study of PROT-001.","status":"COMPLETED","sponsor":"Protego Biopharma Pty Ltd","startDate":"2025-05-29","conditions":"Healthy","enrollment":102},{"nctId":"NCT07032389","phase":"PHASE2","title":"A Polypill for Acute Coronary Syndrome","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-12-05","conditions":"Acute Coronary Syndrome","enrollment":1000},{"nctId":"NCT06553157","phase":"PHASE1, PHASE2","title":"Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy","status":"COMPLETED","sponsor":"Minia University","startDate":"2024-09-01","conditions":"Solid Tumors, Ototoxicity","enrollment":56},{"nctId":"NCT06772168","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia","status":"RECRUITING","sponsor":"CMG Pharmaceutical Co. Ltd","startDate":"2024-04-19","conditions":"Dyslipidemia, Type 2 Diabetes","enrollment":240},{"nctId":"NCT04319627","phase":"PHASE3","title":"Statins for Venous Event Reduction in Patients With Venous Thromboembolism","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2021-02-10","conditions":"Venous Thromboembolism, Blood Clot, Post Thrombotic Syndrome","enrollment":2700},{"nctId":"NCT07344610","phase":"","title":"Effects of Short-term Intensive Statin Therapy on Lipid Levels","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2026-01-08","conditions":"Ischemic Stroke","enrollment":800},{"nctId":"NCT07158398","phase":"PHASE1","title":"Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate","status":"COMPLETED","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2025-10-31","conditions":"Healthy Participants","enrollment":20},{"nctId":"NCT05741372","phase":"NA","title":"A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-09-07","conditions":"Liver Cirrhosis","enrollment":28},{"nctId":"NCT05832229","phase":"PHASE2","title":"Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-12-07","conditions":"Cirrhosis, Cirrhosis, Liver, Cirrhosis Early","enrollment":256},{"nctId":"NCT07097831","phase":"PHASE1","title":"A Clinical Trial of HRS-1301 on the Pharmacokinetics of Rosuvastatin Calcium Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2025-10-09","conditions":"Hyperlipidemia","enrollment":16},{"nctId":"NCT03540355","phase":"PHASE3","title":"Efficacy and Safety of Cipros 20 Association on Dyslipidemia Treatment","status":"COMPLETED","sponsor":"EMS","startDate":"2021-03-02","conditions":"Dyslipidemias","enrollment":406},{"nctId":"NCT06504862","phase":"PHASE1","title":"A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-08-20","conditions":"Healthy","enrollment":32},{"nctId":"NCT06782243","phase":"NA","title":"Comparison of High and Moderate Intensity Statins in Achieving the Target LDL-C Level After Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2024-12-20","conditions":"Acute Coronary Syndrome","enrollment":190},{"nctId":"NCT05579626","phase":"PHASE4","title":"Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)","status":"ENROLLING_BY_INVITATION","sponsor":"Seung-Whan Lee, M.D., Ph.D.","startDate":"2023-03-14","conditions":"Pre Diabetes, ASCVD","enrollment":4000},{"nctId":"NCT04481789","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-10-17","conditions":"Healthy Adult Subjects","enrollment":84},{"nctId":"NCT07313124","phase":"PHASE2, PHASE3","title":"Comparative Study Between Antihyperlipidemic Agents in Treatment of Cardiovascular Diseases","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-12-15","conditions":"Cardiovascular Diseases (CVD)","enrollment":66},{"nctId":"NCT07316608","phase":"PHASE1","title":"A Phase I, Open-label, Crossover Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-16","conditions":"Healthy Participants","enrollment":44},{"nctId":"NCT07269756","phase":"PHASE1","title":"A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2025-12-08","conditions":"Obesity, Overweight","enrollment":40},{"nctId":"NCT07307989","phase":"PHASE2","title":"Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-08-01","conditions":"Ischemic Stroke, Hypercholesteremia","enrollment":300},{"nctId":"NCT07309042","phase":"PHASE1","title":"Phase 1 Study of the Safety and Pharmacokinetics of YN001 With Rosuvastatin in Healthy Chinese Subjects","status":"NOT_YET_RECRUITING","sponsor":"Beijing Inno Medicine Co., Ltd.","startDate":"2025-12","conditions":"Atherosclerotic Cardiovascular Diseases, Cerebrovascular Diseases","enrollment":24},{"nctId":"NCT06501443","phase":"PHASE4","title":"LATAM LOWERS LDL-C","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-11","conditions":"Hypercholesterolaemia","enrollment":520},{"nctId":"NCT07303816","phase":"PHASE4","title":"Statins to Prevent Cancer Associated Blood Clots","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-04-01","conditions":"Venous Thromboembolism, Cancer, Cardiovascular Events","enrollment":4000},{"nctId":"NCT02675309","phase":"PHASE1","title":"A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-02","conditions":"Healthy","enrollment":28},{"nctId":"NCT07215260","phase":"PHASE1","title":"A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2025-11-05","conditions":"Healthy","enrollment":14},{"nctId":"NCT07201545","phase":"PHASE1","title":"Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-10-07","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT07290699","phase":"PHASE4","title":"Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2026-01-01","conditions":"STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)","enrollment":2442},{"nctId":"NCT06896708","phase":"NA","title":"Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome","status":"RECRUITING","sponsor":"Liu yong","startDate":"2025-08-12","conditions":"Chronic Coronary Syndrome","enrollment":766},{"nctId":"NCT07182383","phase":"PHASE1","title":"Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-09-29","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT07128888","phase":"PHASE1","title":"Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection","status":"RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-11-17","conditions":"Obesity or Overweight","enrollment":60},{"nctId":"NCT05444556","phase":"PHASE1","title":"A Study of Imlunestrant (LY3484356) in Female Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-07-07","conditions":"Healthy","enrollment":113},{"nctId":"NCT06317051","phase":"PHASE3","title":"Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2024-12-16","conditions":"HIV Infections, Weight Gain","enrollment":300},{"nctId":"NCT07254221","phase":"PHASE4","title":"Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Shiraz University of Medical Sciences","startDate":"2026-02-01","conditions":"Anthracycline-induced Cardiac Toxicity, Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer","enrollment":400},{"nctId":"NCT03527069","phase":"PHASE3","title":"Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment","status":"COMPLETED","sponsor":"EMS","startDate":"2021-01-29","conditions":"Hypertriglyceridemia, Dyslipidemia","enrollment":146},{"nctId":"NCT04602754","phase":"PHASE3","title":"Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.","status":"RECRUITING","sponsor":"EMS","startDate":"2023-12-01","conditions":"Dyslipidemia Associated With Type II Diabetes Mellitus","enrollment":228},{"nctId":"NCT05064488","phase":"PHASE1","title":"Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2021-10-04","conditions":"Healthy","enrollment":40},{"nctId":"NCT07012629","phase":"PHASE3","title":"A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-26","conditions":"Covert Brain Infarction","enrollment":1652},{"nctId":"NCT07255820","phase":"PHASE4","title":"Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol","status":"NOT_YET_RECRUITING","sponsor":"Bahria University","startDate":"2026-01-01","conditions":"Type 2 Diabetes Mellitus, Hypercholesterolemia / Elevated LDL Cholesterol","enrollment":126},{"nctId":"NCT06791031","phase":"NA","title":"PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-01","conditions":"Coronary Artery Disease","enrollment":212},{"nctId":"NCT04903223","phase":"PHASE1","title":"Liver Adiposity Effects on Pediatric Statin","status":"RECRUITING","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2021-04-01","conditions":"Cholesterol; Lipidosis","enrollment":50},{"nctId":"NCT05910476","phase":"PHASE4","title":"Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2023-05-03","conditions":"Coronary Artery Disease, Dyslipidemias","enrollment":200},{"nctId":"NCT04883840","phase":"PHASE2, PHASE3","title":"Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis","status":"TERMINATED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-10-22","conditions":"Ulcerative Colitis","enrollment":177},{"nctId":"NCT07239414","phase":"PHASE3","title":"Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability","status":"NOT_YET_RECRUITING","sponsor":"Sohaib Ashraf","startDate":"2025-11-10","conditions":"Cardiovascular","enrollment":690},{"nctId":"NCT02117453","phase":"PHASE3","title":"Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-10-27","conditions":"ANCA-associated Primary Necrotizing Vasculitides","enrollment":121},{"nctId":"NCT06975605","phase":"PHASE1","title":"Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.","status":"COMPLETED","sponsor":"GRIN Therapeutics, Inc.","startDate":"2025-05-20","conditions":"Tuberous Sclerosis Complex (TSC), Focal Cortical Dysplasia, Other Neurological Disorders","enrollment":18},{"nctId":"NCT04626973","phase":"NA","title":"Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2021-01-15","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":3048},{"nctId":"NCT06742853","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-12-20","conditions":"Dyslipidemia","enrollment":81},{"nctId":"NCT06948747","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-05-06","conditions":"Healthy Participants","enrollment":49},{"nctId":"NCT06813924","phase":"PHASE1","title":"A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2025-02-06","conditions":"Healthy Volunteers Sickle Cell Disease, Thalassemia","enrollment":37},{"nctId":"NCT04669041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-12-08","conditions":"Hypercholesterolemia","enrollment":305},{"nctId":"NCT05906836","phase":"PHASE1","title":"A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-07-27","conditions":"Healthy","enrollment":28},{"nctId":"NCT06767345","phase":"PHASE4","title":"Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-05-12","conditions":"Coronary Artery Disease, Atherosclerosis of Coronary Artery, Plaque, Atherosclerotic","enrollment":408},{"nctId":"NCT06821698","phase":"PHASE1","title":"To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers","status":"COMPLETED","sponsor":"Kaken Pharmaceutical","startDate":"2025-02-13","conditions":"Healty Volunteers","enrollment":38},{"nctId":"NCT06949124","phase":"PHASE1","title":"A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-04-28","conditions":"Endometriosis, Uterine Fibroids, Assisted Reproduction","enrollment":20},{"nctId":"NCT06358313","phase":"PHASE3","title":"Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Moderate and Moderate-to-severe Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-04-10","conditions":"Ischemic Stroke","enrollment":600},{"nctId":"NCT06360120","phase":"PHASE3","title":"Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-04-10","conditions":"Ischemic Stroke","enrollment":600},{"nctId":"NCT06603363","phase":"NA","title":"Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT","status":"RECRUITING","sponsor":"Prof. Maurovich-Horvat Pál","startDate":"2025-05-28","conditions":"Coronary Artery Disease, Atherosclerotic Plaque, Coronary Computed Tomography Angiography","enrollment":140},{"nctId":"NCT06921941","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-04-08","conditions":"Healthy Volunteer Study","enrollment":38},{"nctId":"NCT05889143","phase":"","title":"A Study to Evaluate the Efficacy and Safety of CREZET Tablet","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2023-05-24","conditions":"Dyslipidemias","enrollment":15000},{"nctId":"NCT05411887","phase":"","title":"Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-06-20","conditions":"Hyperlipidemias, Hypertension","enrollment":2845},{"nctId":"NCT05660135","phase":"","title":"Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-06-20","conditions":"Hypertension, Dyslipidemias","enrollment":4000},{"nctId":"NCT06698666","phase":"PHASE3","title":"Efficacy of Statins Among Major Depressive Disorder","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2022-10-01","conditions":"Major Depressive Disorder, MDD","enrollment":145},{"nctId":"NCT07065058","phase":"PHASE1","title":"A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vincentage Pharma Co., Ltd","startDate":"2025-07-01","conditions":"Obesity &Amp; Overweight","enrollment":24},{"nctId":"NCT04700436","phase":"PHASE4","title":"Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2020-01-03","conditions":"Endocrine System Diseases, Nutritional and Metabolic Diseases, Diabetes Mellitus, Type 2","enrollment":146},{"nctId":"NCT07011992","phase":"PHASE1","title":"A Study to Assess the Effects of BPN14770 on Rosuvastatin","status":"COMPLETED","sponsor":"Shionogi","startDate":"2025-07-18","conditions":"Healthy Participants","enrollment":12},{"nctId":"NCT06071442","phase":"PHASE1","title":"Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-01-17","conditions":"Healthy Participants","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":73,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Crestor"],"phase":"marketed","status":"active","brandName":"Rosuvastatin (Crestor)","genericName":"Rosuvastatin (Crestor)","companyName":"Minneapolis Heart Institute Foundation","companyId":"minneapolis-heart-institute-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rosuvastatin inhibits HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step of cholesterol synthesis in the liver. Used for Hypercholesterolemia and mixed dyslipidemia, Primary prevention of cardiovascular disease in at-risk patients, Secondary prevention of cardiovascular events in patients with established coronary heart disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}